Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075623 | 0.88 | BRAF (0.57) | BRAFCYP2C9 | |
| SCHEMBL19233576 | 0.82 | BRAF (0.59) | BRAFCYP2C9RAF1 | |
| SCHEMBL20577950 | 0.81 | PTGS1 (0.56) | BRAFCYP2C9GAA | |
| SCHEMBL26075610 | 0.81 | BRAF (0.47) | BRAFCYP2C9RAF1 | |
| SCHEMBL26075596 | 0.80 | BRAF (0.56) | BRAFCYP2C9RAF1GAA | |
| SCHEMBL29877734 | 0.80 | BRAF (0.56) | BRAFCYP2C9RAF1 | |
| SCHEMBL26075550 | 0.80 | POLB (0.54) | CYP2C9 | |
| SCHEMBL2192170 | 0.80 | BRAF (0.55) | BRAFCYP2C9RAF1GAA | |
| SCHEMBL26075773 | 0.78 | BRAF (0.53) | BRAFCYP2C9 | |
| SCHEMBL19233286 | 0.78 | KDR (0.56) | BRAFCYP2C9RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | BRAF 21/4885CYP2C9 2592/4885RAF1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.